@entity5 : effective treatment with a combination of XXXX , @entity1891 , and @entity2699 .

@entity1 @entity137 @entity101 @entity2699 @entity5 @entity786 @entity1891 @entity2922 @entity2661 @entity551
STUDY OBJECTIVE: To determine the efficacy and @entity137 of combination chemotherapy in @entity1 with advanced, @entity5 . DESIGN: Nonrandomized, single-arm trial. SETTING: Governmental medical referral center. @entity1 : Fourteen @entity1 with @entity5 confirmed by histologic tests. All @entity1 had metastatic disease and elevated urinary @entity2922 secretion. INTERVENTIONS: After optimization of antihypertensive therapy, @entity1 received @entity786 , 750 mg/m2 body surface area on day 1; @entity1891 , 1.4 mg/m2 on day 1, and @entity2699 , 600 mg/m2 on days 1 and 2, every 21 days. MEASUREMENTS AND MAIN RESULTS: Combination chemotherapy with @entity786 , @entity1891 , and @entity2699 produced a complete and partial response rate of 57% (median duration, 21 months; range, 7 to more than 34). Complete and partial biochemical responses were seen in 79% of @entity1 (median duration, more than 22 months; range, 6 to more than 35). All responding @entity1 had objective improvement in performance status and blood pressure. @entity137 included expected hematologic, neurologic, and gastrointestinal effects of chemotherapy without serious sequelae. There were four minor @entity551 episodes and one minor @entity101 episode. CONCLUSIONS: Combination chemotherapy with @entity786 , @entity1891 , and @entity2699 is effective for advanced @entity5 . Urinary @entity2661 are useful to ascertain biochemical response to therapy.
